A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap/rheumatoid arthritis.
It is commonly believed that infliximab-induced anticardiolipin antibody belongs to the IgM subclass but not the IgG subclass and that the IgM subclass could not produce clinical symptoms. However, we had a patient with scleroderma overlap/rheumatoid arthritis who developed thrombocytopenia associated with the appearance of IgM anticardiolipin antibody after treatment with infliximab. This is a report of a rare case that should make us aware of the possibility of the development of thrombocytopenia with the appearance of IgM anticardiolipin antibody induced by infliximab.
Hamaguchi
Masahide
M
Inflammation and Immunology,Graduate School of Medical Science, 465, Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Kawahito
Yutaka
Y
Ishino
Hidetaka
H
Yoshida
Makie
M
Yoshikawa
Toshikazu
T
D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000097:blood / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000276:immunology; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology; D000069285:Infliximab; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D017153:Antibodies, Anticardiolipin; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007075:Immunoglobulin M; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab